Director George Simeon Buys $27.2M of ADARx Stock at IPO Price
ADRX is trading near its 52-week low of $18.5 (12% above the low).
Summary
Director and 10% owner George Simeon bought $27.2 million of ADARx stock at the $17.00 IPO price on September 28, 2026, alongside the conversion of his affiliated funds' preferred stock into 8.3 million common shares.
Key Events · Ownership and Investor Activity · ADRX
-
Director Buys $27.2M at IPO Price
George Simeon, Director and 10% Owner, purchased 1,600,000 shares at $17.00 per share for $27,200,000 on September 28, 2026 — the IPO closing date.
-
Preferred Stock Converts to Common
Simeon's affiliated SR One entities converted Series B, B-1, and C preferred stock into 8,336,661 common shares upon the IPO closing, a routine follow-through of the $446.3 million offering.
-
Post-Transaction Holdings
Following the transactions, Simeon's indirect holdings total 19,704,730 shares across SR One Capital Management entities, with 5,554,094 shares held directly.
-
IPO Context
The purchase occurred at the $17.00 IPO price, which was set on September 26, 2026; the stock traded at $20.63 as of September 29, 2026.
Analysis · ADRX · Life Sciences
A key insider is putting significant capital to work at the offering price. George Simeon, a Director and 10% Owner of ADARx Pharmaceuticals, purchased 1.6 million shares at $17.00 per share for $27.2 million on September 28, 2026 — the same day the company closed its $446.3 million IPO. This substantial open-market purchase represents real capital deployment alongside the public offering. The filing also reflects the automatic conversion of Simeon's affiliated SR One entities' preferred stock into 8.3 million common shares upon the IPO closing, a routine follow-through of the previously disclosed offering. The $27.2 million purchase is the material new fact here — a director and major shareholder putting significant money to work at the offering price, which typically signals conviction in the company's valuation and prospects.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1052 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADRX was trading at $20.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $18.50 to $23.21. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.